Onyx’s Cancer Drug’s Risk May Outweigh Benefit, FDA Says
This article is for subscribers only.
Onyx Pharmaceuticals Inc. fell the most in two weeks after U.S. regulators said its drug for a deadly blood cancer may not offer enough benefits over current therapies to outweigh risks including chest pain and pneumonia.
Onyx dropped 4.1 percent to $44.08 at the close in New York, the biggest single-day decline since June 4.